Clinical Experience & Use
- Clinical Data
- Indication
- Dosing
- Side Effects and Coping
- Mechanism of Action
- Full Prescribing Information
Education & Support
- Expert Viewpoints
- Strategies to Improve Adherence
- Patient Support Programs
- Educational Materials
- e-Details
- Additional Resources
Register for Site Updates

Education & Support

Additional Resources

Additional resources

For more information, click on the links below:

AstraZeneca Oncology Professional Web Sites +-

AstraZeneca Oncology Consumer Web Sites +-

Other Professional Resources +-

The organizations and Web sites listed below may be of interest to oncology professionals.

The following list of resources is provided merely as a convenience. AstraZeneca takes no responsibility for the content of, or services provided by, these resources, and makes no representations as to the accuracy or completeness of any information provided. AstraZeneca shall have no liability for any damages or injuries of any kind arising from the information provided.

American Academy of Family Physicians
11400 Tomahawk Creek Parkway
Leawood, KS 66211-2672
Phone: 800-274-2237
www.aafp.org

American Academy of Hospice and Palliative Medicine
4700 W. Lake Ave.
Glenview, IL 60025-1485
Phone: 847-375-4712
E-mail: info@aahpm.org
www.aahpm.org

American Cancer Society
1180 Avenue of the Americas
New York, NY 10036
Phone: 1-800-227-2345
www.cancer.org

American College of Obstetricians and Gynecologists
409 12th Street, SW
PO Box 96920
Washington, DC 20090
Phone: 202-638-5577
www.acog.com

American Medical Women's Association
100 N. 20th Street, 4th Floor
Philadelphia, PA 19103
Phone: 215-320-3716
www.amwa-doc.org

American Nurses Association
8515 Georgia Avenue
Suite 400
Silver Spring, MD 20910
Phone: 301-628-5000 or 800-274-4ANA (4262)
Fax: 301-628-5001
www.nursingworld.org

American Pain Foundation
201 N. Charles Street, Suite 710
Baltimore, MD 21201-4111
Phone: 888-615-PAIN (7246)
E-mail: info@painfoundation.org
www.painfoundation.org/default.asp

American Society of Clinical Oncology
2318 Mill Road, Suite 800
Alexandria, VA 22314
Phone: 703-299-0150
www.asco.org

CancerCare, Inc.
275 Seventh Avenue
New York, NY 10001
Phone: 212-721-8400 or 800-813-4673
www.cancercare.org

Centers for Disease Control and Prevention
Office of Program and Policy Information
National Center for Chronic Disease Prevention and Health Promotion
Division of Cancer Prevention and Control
4770 Bulford Highway, NE
Mail Stop K64
Atlanta, GA 30341-3717
Phone: 800-CDC-INFO
Fax: 770-488-4760
E-mail: cdcinfo@cdc.gov
www.cdc.gov/cancer/nbccedp

End-of-Life Nursing Education Consortium (ELNEC) Project
American Association of Colleges of Nursing
One Dupont Circle, NW, Suite 530
Washington, DC 20036
Phone: 202-463-6930
Fax: 202-785-8320
www.aacn.nche.edu/elnec

National Cancer Institute
NCI Public Inquiries Office
6116 Executive Boulevard
Room 3036A
Bethesda, MD 20892-8322
Phone: 800-4-CANCER
www.cancer.gov

National Medical Association
1012 10th Street, NW
Washington, DC 20001
Phone: 202-347-1895
Fax: 202-898-2510
www.nmanet.org

Oncology Nursing Society
125 Enterprise Drive
Pittsburgh, PA 15275
Phone: 866-257-4ONS or 412-859-6100
Fax: 877-369-5497 (toll-free) or 412-859-6162
E-mail: customer.service@ons.org
www.ons.org

Prevent Cancer Foundation
1600 Duke Street, Suite 110
Alexandria, VA 22314
Phone: 703-836-4412
www.preventcancer.org

Other Patient Resources +-

Patients currently undergoing treatment for breast cancer may find the following consumer sites of interest and helpful as their course of treatment proceeds.

American Cancer Society
1180 Avenue of the Americas
New York, NY 10036
Phone: 800-227-2345
or
1599 Clifton Road, NE
Atlanta, GA 30329
www.cancer.org

BreastCancer.org
7 East Lancaster Ave.
3rd Floor
Ardmore, PA 19003
www.breastcancer.org

Breast Cancer Network of Strength
212 W. Van Buren, Tenth Floor
Chicago, IL 60607-3903
Phone: 312-986-8338
Fax: 312-294-8598
www.networkofstrength.org

CancerCare, Inc.
275 Seventh Avenue
New York, NY 10001
Phone: 212-721-8400 or 800-813-4673
www.cancercare.org

Centers for Disease Control and Prevention
Program and Policy Information Division of Cancer Prevention and Control
4770 Bulford Highway, NE
Mail Stop K-64
Atlanta, GA 30341-3717
Phone: 800-CDC-INFO
E-mail: cdcinfo@cdc.gov
www.cdc.gov/cancer/nbccedp

National Cancer Institute
NCI Public Inquiries Office
6116 Executive Boulevard
Room 3036
Bethesda, MD 20892-8322
Phone: 800-4-CANCER
www.cancer.gov

National Alliance of Breast Cancer Organizations (NABCO)
9 East 37th Street
New York, NY 10016
Phone: 888-80-NABCO
www.nabco.org

Oncology Nursing Society
125 Enterprise Drive
Pittsburgh, PA 15275
Phone: 866-257-4ONS or 412-859-6100
Fax: 877-369-5497 (toll-free) or 412-859-6162
E-mail: customer.service@ons.org
www.ons.org

OncoLink Editorial Board
Abramson Cancer Center of the University of Pennsylvania
3400 Spruce Street, 2 Donner
Philadelphia, PA 19104-4283
E-mail: webmaster@oncolink.com
www.oncolink.upenn.edu

Prevent Cancer Foundation
1600 Duke Street, Suite 110
Alexandria, VA 22314
Phone: 703-836-4412
www.preventcancer.org

Susan G. Komen for the Cure
5005 LBJ Freeway, Suite 250
Dallas, TX 75244
Phone: 972-855-1600 or 1-877-GO-KOMEN
www.breastcancerinfo.com

The National Breast Cancer Coalition
1101 17th Street, NW, Suite 1300
Washington, DC 20036
Phone: 800-622-2838 or 202-296-7477
Fax: 202-265-6854
www.stopbreastcancer.org

A A Atext size

tell a friend

Important Information About ARIMIDEX^® (anastrozole) Tablets

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is indicated for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

ARIMIDEX is only for postmenopausal women. ARIMIDEX can cause fetal harm when administered to a pregnant woman. Before starting treatment with ARIMIDEX, pregnancy must be excluded (see WARNINGS section of full Prescribing Information).

In women with preexisting ischemic heart disease 465/6186 (7.5%), an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX (17%) vs tamoxifen (10%). In this patient population, angina pectoris was reported in 25/216 (11.6%) vs 13/249 (5.2%) and myocardial infarction was reported in 2/216 (0.9%) vs 8/249 (3.2%) patients receiving ARIMIDEX and tamoxifen, respectively.

Compared to baseline, ARIMIDEX showed a mean decrease in both lumbar spine and total hip bone mineral density. Tamoxifen showed a mean increase in these measurements. Nine percent of patients receiving ARIMIDEX had an elevated serum cholesterol vs 3.5% of patients receiving tamoxifen.

Common side effects seen with ARIMIDEX vs tamoxifen in the early breast cancer trial after 5 years of treatment include hot flashes (36% vs 41%), joint disorders (including arthritis, arthrosis, arthralgia) (36% vs 29%), asthenia (19% vs 18%), mood disturbances (19% vs 18%), pain (17% vs 16%), pharyngitis (14% vs 14%), nausea and vomiting (13% vs 12%), rash (11% vs 13%), depression (13% vs 12%), hypertension (13% vs 11%), osteoporosis (11% vs 7%), peripheral edema (10% vs 11%), lymphedema (10% vs 11%), back pain (10% vs 10%), insomnia (10% vs 9%), and headache (10% vs 8%). Fractures, including fractures of the spine, hip, and wrist, occurred more often with ARIMIDEX vs tamoxifen (10% vs 7%).

In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking ARIMIDEX included hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis, and peripheral edema. Joint pain/stiffness has been reported in association with the use of ARIMIDEX.

Clinical and pharmacokinetic results suggest that tamoxifen should not be administered with ARIMIDEX. Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

Please click here for full Prescribing Information.

Important Information About FASLODEX Injection

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Important Safety Information About FASLODEX

FASLODEX is only for postmenopausal women. FASLODEX can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while receiving FASLODEX. (See CONTRAINDICATIONS and WARNINGS sections of full Prescribing Information.)

Because FASLODEX is administered intramuscularly, it should not be used in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants.

In clinical trials, the most commonly reported adverse effects seen with FASLODEX, regardless of the investigator’s assessment of causality, were gastrointestinal symptoms (nausea 26%, vomiting 13%, constipation 12.5%, diarrhea 12.3%, abdominal pain 11.8%), headache (15.4%), back pain (14.4%), hot flashes (17.7%), and pharyngitis (16.1%). Injection site reactions with mild, transient pain and inflammation were reported in 7% of patients (1% of treatments) given a single 5 mL injection and 27% of patients (4.6% of treatments) given 2 x 2.5 mL injections of FASLODEX.

Please click here for full Prescribing Information.

This product information is intended for US professionals only.

ARIMIDEX and FASLODEX are registered trademarks and Celebration Chain, In Your Corner, and Leading Ladies are trademarks of the AstraZeneca group of companies.

Education & Support

Additional Resources